New real-world evidence.
Comparative effectiveness of ambulatory monitors for arrhythmia diagnosis (CAMELOT).
The first and largest study of its kind found Zio XT monitoring is associated with the highest diagnostic yield and lowest likelihood of retesting.1,2
Study design and methodology
The claims represent the coding that providers used to document the care they provided to their patients and the follow-up paths those same patients followed. The only claims included in the analysis were for patients who had not had previous cardiac monitoring, resulting in a balanced and comprehensive comparison of retest and healthcare resource utilization.
The study cohort of 287,789 diagnostic-naïve patients was derived from the full Medicare fee-for-service data set of 1,582,784.
The first and largest retrospective claims analysis using Medicare fee-for-service documentation.1,2
The cohort included 287,789 patients.
Study Period and Example Index Date, Baseline Period, and Follow-up Period
See the poster
See the poster
Fill out the form to download the poster.
Subscribe to our newsletter to get Zio updates in your inbox.
- Reynolds et al. Comparative effectiveness of ambulatory monitors for arrhythmia diagnosis: A retrospective analysis of Medicare beneficiaries managed with ambulatory cardiac monitors between 2017 and 2019. Accepted for ACC.23 presentation, presented in New Orleans, LA.
- Data on file. iRhythm Technologies, 2023.
- Specified arrhythmias defined by Hierarchical Condition Categories (HCC) 96.